Abstract
Purpose. An integrated receptor-based pharmacokinetic/pharmaco- dynamic (PK/PD) model of interferon-β 1a (IFN-β 1a) previously developed for monkeys was used to capture the time-course of drug and induced neopterin concentrations after intravenous (IV) and subcutaneous (SC) dosing in humans.
Methods. Data were extracted from the literature by digitalization. Single-dose (3 IV doses and 1 SC dose) PK/PD profiles were simultaneously fitted using the basic model and the ADAPT II computer program. Additional submodels incorporating neutralizing antibody formation and negative feedback inhibition were applied to account for drug accumulation and lower than expected neopterin concentrations encountered after multiple-dosing (1 SC dose every 48 hs).
Results. The basic model jointly-captured the nonlinear PK behavior of the drug and induced neopterin concentrations after all single doses. Slow and incomplete absorption (F = 0.33) of the SC dose resulted in prolonged drug concentrations reflective of flip-flop kinetics. Despite lower drug concentrations, SC dosing produced a similar neopterin profile as compared with the IV doses; however, with a longer time to peak effect and slightly higher neopterin concentrations at later time points. The PD component of the model represents a modified precursor-dependent indirect response model driven by the amount of internalized drug-receptor complex. The latter stimulated a 6-fold increase in the production of the neopterin precursor (Smax = 5.89). Drug accumulation and lower than expected neopterin concentrations after multiple dosing were also captured after the inclusion of the submodels.
Conclusions. The present integrated PK/PD model for IFN-β 1a is mechanistic in nature with receptor-mediated disposition and dynamics and was successfully applied to human clinical data.
Similar content being viewed by others
REFERENCES
J. H. Noseworthy, C. Lucchinetti, M. Rodriguez, and B. G. Weinshenker. Multiple sclerosis. N.Engl.J.Med. 343:938-952 (2000).
W. Leonard. Type I cytokines and interferons and their receptors. In W. Paul (ed.), Fundamental Immunology, Lippincott-Raven, Philadelphia, Pennsylvania, 1999 pp. 741-774.
S. Pestka, J. A. Langer, K. C. Zoon, and C. E. Samuel. Interferons and their actions. Annu.Rev.Biochem. 56:727-777 (1987).
J. Alam, S. Goelz, P. Rioux, J. Scaramucci, W. Jones, A. McAllister, M. Campion, and M. Rogge. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers. Pharm.Res. 14:546-549 (1997).
J. Chiang, C. A. Gloff, C. N. Yoshizawa, and G. J. Williams. Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin. Pharm.Res. 10:567-572 (1993).
G. Fierlbeck, A. Ulmer, T. Schreiner, W. Stroebel, U. Schiebel, and J. Brzoska. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma. J.Interferon Cytokine Res. 16:777-781 (1996).
L. E. Rothuizen, T. Buclin, F. Spertini, I. Trinchard, A. Munafo, P. A. Buchwalder, A. Ythier, and J. Biollaz. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biologic effect markers. J.Neuroimmunology 99:131-141 (1999).
P. Salmon, J. Y. Le Cotonnec, A. Galazka, A. Abdul-Ahad, and A. Darragh. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J.Interferon Cytokine Res. 16:759-764 (1996).
D. E. Mager, B. Neuteboom, A. Murafo, C. Efthymiopoulos, and W. J. Jusko. Receptor-mediated pharmacokinetics and pharmacodynamics of IFN-beta 1a following intravenous and subcutaneous dosing in monkeys. In Pharmaceutical Congress of the Americas. AAPS, Orlando, Florida, 2001.
D. E. Mager and W. J. Jusko. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J.Pharmacokinet.Pharmacodyn. 28:507-532 (2001).
P. A. Buchwalder, T. Buclin, I. Trinchard, A. Munafo, and J. Biollaz. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J.Interferon Cytokine Res. 20:857-866 (2000).
K. C. Zoon and H. Arnheiter. Studies of the interferon receptors. Pharmacol.Ther. 24:259-278 (1984).
E. Radwanski, A. Chakraborty, S. Van Wart, R. D. Huhn, D. L. Cutler, M. B. Affrime, and W. J. Jusko. Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharm.Res. 15:1895-1901 (1998).
A. Supersaxo, W. Hein, and H. Steffen. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm.Res. 7:167-169 (1990).
D. Fuchs, G. Weiss, G. Reibnegger, and H. Wachter. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit.Rev.Clin.Lab.Sci. 29:307-341 (1992).
A. Sharma, W. F. Ebling, and W. J. Jusko. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J.Pharm.Sci. 87:1577-1584 (1998).
R. Braeckman. Pharmacokinetics and pharmacodynamics of protein therapeutics. In R. E. Reid (ed.), Peptide and Protein Drug Analysis, University of British Columbia, Vancouver, 1999 pp. 633-669.
N. L. Dayneka, V. Garg, and W. J. Jusko. Comparison of four basic models of indirect pharmacodynamic responses. J.Pharmacokinet.Biopharm. 21:457-478 (1993).
H. Cheng, A. Staubus, and L. Shum. An area function method for estimating the apparent absorption rate constant. Pharm.Res. 5:57-60 (1988).
D. Z. D'Argenio and A. Schumitzky. ADAPT II user's guide. Biomedical Simulations Resource, Los Angeles, California, 1997.
S. D. Cook, J. R. Quinless, A. Jotkowitz, P. Beaton, and the Neutralizing Antibody Study Group. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology 57:1080-1084 (2001).
Y. Sugiyama and M. Hanano. Receptor-mediated transport of peptide hormones and its importance in the overall hormone disposition in the body. Pharm.Res. 6:192-202 (1989).
G. Levy. Pharmacologic target-mediated drug disposition. Clin.Pharmacol.Ther. 56:248-252 (1994).
G. Stark, I. Kerr, B. Williams, R. Silverman, and R. Schreiber. How cells respond to interferons. Annu.Rev.Biochem. 67:227-264 (1998).
A. M. Liberati, M. Fizzotti, M. G. Proietti, R. Di Marzio, M. Schippa, B. Biscottini, M. Senatore, P. Berruto, S. Canali, G. Peretti, and G. Zanolo. Biochemical host response to interferonbeta. J.Interferon Res. 8:765-777 (1988).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mager, D.E., Jusko, W.J. Receptor-Mediated Pharmacokinetic/Pharmacodynamic Model of Interferon-β 1a in Humans. Pharm Res 19, 1537–1543 (2002). https://doi.org/10.1023/A:1020468902694
Issue Date:
DOI: https://doi.org/10.1023/A:1020468902694